H.C. Wainwright Reiterates Neutral Rating on Outlook Therapeutics Incs. (OTLK)

September 30, 2025 6:54 AM EDT Send to a Friend
H.C. Wainwright analyst Douglas Tsao reiterated a Neutral rating and $1.00 price target on Outlook Therapeutics Incs. (NASDAQ: OTLK).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login